Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting retrovirus entry

F L Cosset1, S J Russell

  • 1Centre de Génétique Moléculaire et Cellulaire, CNRS UMR5534, Université Claude-Bernard Lyon-1, Villeurbanne, France.

Gene Therapy
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PIWIs, piRNAs and Retrotransposons: Complex battles during reprogramming in gametes and early embryos.

Reproduction in domestic animals = Zuchthygiene·2017
Same author

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood cancer journal·2017
Same author

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Leukemia·2017
Same author

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Leukemia·2017
Same author

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Blood cancer journal·2017
Same author

Natural history of t(11;14) multiple myeloma.

Leukemia·2017
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
Same journal

Environmental and developmental factors shape anti-AAV immunity in pigs.

Gene therapy·2026
See all related articles

Developing targeted gene therapy vectors is crucial for expanding treatment options. Researchers are engineering retroviral vectors with specific envelope glycoproteins for precise in vivo gene delivery to target cells.

Area of Science:

  • Gene therapy
  • Retroviral vectors
  • Molecular biology

Background:

  • Current gene therapy primarily uses ex vivo methods, modifying cells outside the body.
  • In vivo gene delivery to specific cells remains a significant challenge for broader gene therapy applications.

Purpose of the Study:

  • To review advancements in developing retroviral vectors for targeted in vivo gene therapy.
  • To explore engineered envelope glycoproteins for enhanced vector specificity.

Main Methods:

  • Review of recent research on retroviral vector development.
  • Focus on modifications of envelope glycoproteins for target cell recognition.

Main Results:

  • Engineered envelope glycoproteins show promise for specific gene delivery.

Related Experiment Videos

  • Retroviral vectors are being adapted for improved in vivo targeting.

    • Conclusions:

    • Targeted in vivo gene delivery via engineered retroviral vectors is a key area for gene therapy advancement.
    • Improved vector specificity will expand the therapeutic potential of gene therapy.